MY206140A - Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof - Google Patents
Bispecific anti-cd28 x anti-cd22 antibodies and uses thereofInfo
- Publication number
- MY206140A MY206140A MYPI2021003083A MYPI2021003083A MY206140A MY 206140 A MY206140 A MY 206140A MY PI2021003083 A MYPI2021003083 A MY PI2021003083A MY PI2021003083 A MYPI2021003083 A MY PI2021003083A MY 206140 A MY206140 A MY 206140A
- Authority
- MY
- Malaysia
- Prior art keywords
- antigen
- antibodies
- binding molecules
- bispecific antigen
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781689P | 2018-12-19 | 2018-12-19 | |
| PCT/US2019/067173 WO2020132066A1 (en) | 2018-12-19 | 2019-12-18 | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY206140A true MY206140A (en) | 2024-11-30 |
Family
ID=69182681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021003083A MY206140A (en) | 2018-12-19 | 2019-12-18 | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
Country Status (16)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119143875A (zh) * | 2018-06-21 | 2024-12-17 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| KR20210104836A (ko) * | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
| EP3941941A1 (en) * | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| JP7905328B2 (ja) | 2020-09-18 | 2026-08-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Cd38及び/又はcd28を結合する抗原結合分子及びその使用 |
| CN116635425A (zh) * | 2020-11-03 | 2023-08-22 | 德国癌症研究中心公共法律基金会 | 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体 |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| EP4490192A1 (en) | 2022-03-07 | 2025-01-15 | Novimmune S.A. | Cd28 bispecific antibodies for targeted t cell activation |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| AU2023254191A1 (en) * | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023198042A1 (zh) * | 2022-04-11 | 2023-10-19 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和cd28的抗原结合分子及其医药用途 |
| CN117264065B (zh) * | 2022-06-15 | 2025-11-18 | 三优生物医药(上海)有限公司 | 一种her2抗原结合分子及其应用 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024077268A2 (en) * | 2022-10-07 | 2024-04-11 | Fred Hutchinson Cancer Center | Human metapneumovirus antibodies and uses thereof |
| AU2023362569A1 (en) | 2022-10-21 | 2025-04-24 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| JP2026508624A (ja) | 2023-03-13 | 2026-03-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗cd22×抗cd28分子でがんを治療する方法 |
| CN120904324A (zh) * | 2024-04-30 | 2025-11-07 | 惠和生物技术(上海)有限公司 | 抗cd28抗体及其用途 |
| WO2026078067A1 (en) | 2024-10-08 | 2026-04-16 | Novimmune Sa | Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof |
| US20260146100A1 (en) | 2024-10-30 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| WO2008038587A1 (fr) | 2006-09-25 | 2008-04-03 | National University Corporation Nagoya University | Lignée cellulaire du lymphome b malin modifié négativement par cd20 |
| US20130079353A1 (en) | 2009-12-22 | 2013-03-28 | Karsten Gülow | Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014044793A2 (en) | 2012-09-20 | 2014-03-27 | Max-Delbrück-Centrum für Molekulare Medizin | Cd22-binding peptides |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| EP3541843A1 (en) * | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| AU2019315440B2 (en) * | 2018-07-30 | 2025-03-13 | Angeles Therapeutics, Inc. | Improving the efficacy and safety of adoptive cellular therapies |
| CN109021114B (zh) * | 2018-08-08 | 2020-06-09 | 武汉波睿达生物科技有限公司 | 联合两种单链抗体的双特异性嵌合抗原受体及表达载体 |
| KR20210104836A (ko) * | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
-
2019
- 2019-12-18 KR KR1020217022524A patent/KR20210104836A/ko active Pending
- 2019-12-18 MX MX2021007497A patent/MX2021007497A/es unknown
- 2019-12-18 MA MA054540A patent/MA54540A/fr unknown
- 2019-12-18 AU AU2019405747A patent/AU2019405747B2/en active Active
- 2019-12-18 CN CN201980080109.1A patent/CN113164598B/zh active Active
- 2019-12-18 US US16/719,015 patent/US11396544B2/en active Active
- 2019-12-18 MY MYPI2021003083A patent/MY206140A/en unknown
- 2019-12-18 PH PH1/2021/551401A patent/PH12021551401A1/en unknown
- 2019-12-18 WO PCT/US2019/067173 patent/WO2020132066A1/en not_active Ceased
- 2019-12-18 EP EP19839551.9A patent/EP3897715A1/en active Pending
- 2019-12-18 BR BR112021010238-8A patent/BR112021010238A2/pt unknown
- 2019-12-18 JP JP2021531128A patent/JP7637052B2/ja active Active
- 2019-12-18 EA EA202191580A patent/EA202191580A1/ru unknown
-
2021
- 2021-06-13 IL IL283945A patent/IL283945A/en unknown
- 2021-06-17 CL CL2021001630A patent/CL2021001630A1/es unknown
- 2021-07-08 CO CONC2021/0009004A patent/CO2021009004A2/es unknown
-
2022
- 2022-06-21 US US17/844,814 patent/US20230174652A1/en not_active Abandoned
-
2024
- 2024-10-31 JP JP2024192042A patent/JP7882920B2/ja active Active
-
2025
- 2025-01-30 US US19/040,913 patent/US20250223360A1/en active Pending
-
2026
- 2026-03-05 JP JP2026035546A patent/JP2026088139A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11396544B2 (en) | 2022-07-26 |
| JP2025013425A (ja) | 2025-01-24 |
| CL2021001630A1 (es) | 2021-12-17 |
| EA202191580A1 (ru) | 2021-11-01 |
| WO2020132066A1 (en) | 2020-06-25 |
| AU2019405747B2 (en) | 2026-08-06 |
| JP2026088139A (ja) | 2026-05-28 |
| MX2021007497A (es) | 2021-08-05 |
| BR112021010238A2 (pt) | 2021-08-24 |
| KR20210104836A (ko) | 2021-08-25 |
| JP7637052B2 (ja) | 2025-02-27 |
| US20200239576A1 (en) | 2020-07-30 |
| US20250223360A1 (en) | 2025-07-10 |
| WO2020132066A8 (en) | 2020-07-30 |
| EP3897715A1 (en) | 2021-10-27 |
| AU2019405747A1 (en) | 2021-06-17 |
| CA3124168A1 (en) | 2020-06-25 |
| CO2021009004A2 (es) | 2021-07-30 |
| US20230174652A1 (en) | 2023-06-08 |
| CN113164598B (zh) | 2025-04-25 |
| IL283945A (en) | 2021-07-29 |
| CN113164598A (zh) | 2021-07-23 |
| JP2022510964A (ja) | 2022-01-28 |
| JP7882920B2 (ja) | 2026-06-30 |
| PH12021551401A1 (en) | 2022-05-11 |
| MA54540A (fr) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551401A1 (en) | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof | |
| MY208537A (en) | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof | |
| MX2020013804A (es) | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. | |
| JOP20200237A1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
| MX2025005515A (es) | Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos | |
| PH12019500604A1 (en) | Anti-muc16 (mucin 16) antibodies | |
| MY195059A (en) | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof | |
| MY202870A (en) | Anti-ctla-4 antibodies and uses thereof | |
| WO2020121195A8 (en) | Trem2 antibodies and uses thereof | |
| MX2019005911A (es) | Anticuerpos anti_cd137 novedosos y usos de estos. | |
| MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
| EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
| JO3736B1 (ar) | جزيئات رابطة لـ pd-1 وطرق استخدامها | |
| SA523440622B1 (ar) | أجسام مضادة | |
| GEAP202114964A (en) | ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF | |
| EP4541819A3 (en) | Anti-cd3 epsilon antibodies | |
| GEP20237484B (en) | Antibody variants | |
| EA202191677A1 (ru) | Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения | |
| EA202190089A1 (ru) | Биспецифичные антитела анти-psma x анти-cd28 и их применения | |
| TH1901001723A (th) | แอนติ-muc16 แอนติบอดี, คอยจูเกตของแอนติบอดี-ยา, และโมเลกุลที่จับกับไบสเปซิฟิกแอนติเจนที่ซึ่งจับ muc16 และ cd3, และการใช้พวกมัน |